Market Overview

Flu Activity Continues to Rise, Related Prescriptions Up 12% from Last Week; Watch CVS, Walgreen

Share:
Related CVS
Consumer Staple ETFs Remain Steady In 2015
TargetExpress Concept 'Gaining Traction' In Testing, Deutsche Bank Says
Steven Romick Sells Stakes in 4 Companies (GuruFocus)
Related WAG
IPO Outlook: API-Focused Software Tech Company Apigee Is A Silent Growth Story
Jana Partners' Barry Rosenstein: 'The Walgreens Situation Is Terrific'

Lazard Capital Market's Tom Galluci issued an update on flu activity Monday morning following a note from December 17th which suggested CVS (NYSE: CVS) and Walgreen (NYSE: WAG) could benefit from increased cases of the virus.

The analyst said flu activity was up 12 percent from last week and up a very concerning 94 percent from the same week last year. Prescriptions for cold, cough and/or flu drugs has surged 61 percent from December 2011.

Galluci believes this increase in activity is likely to have a greater effect on hospital volume metrics rather than earnings as a lower-margin business.

Lazard maintains a Buy rating on CVS and a Neutral rating on Walgreen shares.

Latest Ratings for CVS

DateFirmActionFromTo
Jun 2015OppenheimerInitiates Coverage onOutperform
Jun 2015Cowen & CompanyMaintainsOutperform
Jun 2015MacquarieInitiates Coverage onOutperform

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (CVS + RAD)

Around the Web, We're Loving...

Get Benzinga's Newsletters